Munich - Delayed Quote • EUR Cue Biopharma Inc (1UC.MU) Follow 1.3400 -0.0100 (-0.74%) At close: April 26 at 8:03 AM GMT+2 Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for 1UC.MU 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: 1UC.MU View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Here's Why Cue Biopharma (CUE) is Poised for a Turnaround After Losing -22.83% in 4 Weeks Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now Q4 2023 Cue Biopharma Inc Earnings Call Cue Biopharma Inc (CUE) Q4 2023 Earnings Call Transcript Highlights: Strategic Alliances and ... Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights Cue Biopharma to Host Business Update Call and Webcast Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength? Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference Cue Biopharma (NASDAQ:CUE) investors are sitting on a loss of 80% if they invested three years ago
